Boston, MA, 02/21/2014 – MannKind Corporation (NASDAQ:MNKD) reported bigger-than- expected loss this Wednesday in its fourth quarter reports. The company’s net loss came widely below at ($0.16) than the market consensus of ($0.14), however, still the numbers were far better then the previous year’s Q4 loss, which was at ($0.23) per share. Like previous year’s quarter, MannKind did not generate revenue around this period as well. For the year 2013, MannKind Corporation (NASDAQ:MNKD)‘s loss was at 64 cents per share, below than the estimated 62 cents per share. Research & Development expenses were among the highest posting increase of 14.7% or $29 million. The key development for the company right now is its impending review from FDA for Afrezza, which is expected to come around April 15th’ 2014.
Mylan Inc (NASDAQ:MYL) has been soaring high ever since the announcement of the Actavis acquisition of Forest Laboratory surfaced. On Feb. 18, Actavis Plc (NYSE:ACT) announced that it is taking over Forest laboratories Inc. (NYSE:FRX) for a consideration of $25 billion, which resulted in an upsurge in Forest’s shares. The announcement resulted in Mylan Inc (NASDAQ:MYL)’s shares to climb over too fueled by speculations that it too could be acquired soon. However, experts believe that these speculations, whatsoever, are ill-informed and are not supported by facts.
Merck & Co., Inc. (NYSE:MRK) issued a statement on Thursday, announcing that the U.S. Food and Drug Administration (FDA) have accepted the marketing application of its drug V503. V503 is a vaccine to protect against four types of human papillomavirus (HPV), which its Gardasil protects alongwith additional five viruses which can cause cervical and other types of cancer. The increased coverage might not result in more prescriptions, but it could definitely take on GalxoSmithKline in sales. The trial data for V503 have showed its efficacy and Merck & Co., Inc. (NYSE:MRK) should be able to receive approval within a year of its submission of application to the FDA.